July 15, 2016
TD2’s VP of Nonclinical Operations, Paul Gonzales, will be presenting at the upcoming 4th Annual Tumor Models – Boston (www.tumor-models.com) on Wednesday, July 20th. The topic of the presentation is The Role of the Gut Microbiome on the Anti-Tumor Response of Immune Checkpoint Inhibitors in a Syngeneic Murine Model of HPV-Associated Cancer.
Contact us if you’re interested in a copy of the presentation.
Effective site selection is critical to the success of any clinical trial, especially in oncology, where patient recruitment can be particularly ...
Diet-induced obesity (DIO) mouse models are integral to the exploration of obesity's role in cancer etiology, offering detailed insights into the ...
The Challenge: Overcoming Inefficiencies in Trial Start-Up The period between receiving the FDA’s “May Proceed” letter and activating trial sites for ...
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
© 2024 Translational Drug Development. All Rights Reserved. Terms and Conditions | Privacy Policy
